Treats hypertension. ANDA 91497, held by Prinston Pharmaceutical. Losartan Potassium.
As of Nov 21, 2026, ANDA 91497 (Losartan Potassium), held by Prinston Pharmaceutical, was first approved by FDA on Jun 6, 2011, with 6 approved supplements and 0 published complete response letters.
Losartan potassium is an angiotensin II receptor blocker (ARB) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 6, 2011 | Original application | Approved | None posted |
| Losartan Potassium25MG ยท tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG ยท tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG ยท tablet;oral | Losartan Potassium | Rx |
| Apr 12, 2017 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Apr 12, 2017 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Feb 13, 2015 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Dec 11, 2014 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Dec 11, 2014 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Dec 19, 2012 | Supplement 1Labeling | Approved | None posted |
| Jun 6, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters